TY - JOUR
T1 - Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
AU - Song, Jeong Eun
AU - Kim, Do Young
N1 - Publisher Copyright:
© 2017 Baishideng Publishing Group Inc. All rights reserved.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/6/28
Y1 - 2017/6/28
N2 - Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediatestage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drugeluting beads (DEBs) have been imposed as novel drugdelivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEBTACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.
AB - Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediatestage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drugeluting beads (DEBs) have been imposed as novel drugdelivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEBTACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.
UR - http://www.scopus.com/inward/record.url?scp=85021181621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021181621&partnerID=8YFLogxK
U2 - 10.4254/wjh.v9.i18.808
DO - 10.4254/wjh.v9.i18.808
M3 - Short survey
AN - SCOPUS:85021181621
VL - 9
SP - 808
EP - 814
JO - World Journal of Hepatology
JF - World Journal of Hepatology
SN - 1948-5182
IS - 18
ER -